ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,965Medicare Part D Prescriptions Filled, Including Refills

Rank: 221 out of 890

$534K Total Retail Price of All Prescriptions

Rank: 226 out of 890

408 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
48% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

12% of this provider’s 408 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

5% of this provider’s 8,070 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
OMEPRAZOLE 353 285 1 8
HYDROCODONE-ACETAMINOPHEN 344 260 S3 2 3
LEVOTHYROXINE SODIUM 262 220 3 2
HYDROCHLOROTHIAZIDE 246 210 4 9
FUROSEMIDE 203 190 5 7
GLYBURIDE 202 153 R 6 83
AMLODIPINE BESYLATE 197 150 7 1
ENALAPRIL MALEATE 196 161 8 56
LISINOPRIL 193 145 9 4
SIMVASTATIN 179 152 10 5
POTASSIUM CHLORIDE 168 141 11 11
ATENOLOL 168 114 11 23
NAMENDA 162 162 13 36
MIRTAZAPINE 160 131 14 82
TRAMADOL HCL 148 134 15 16
METFORMIN HCL 146 101 16 6
DONEPEZIL HCL 135 135 17 30
POLYETHYLENE GLYCOL 3350 129 118 18 67
CITALOPRAM HBR 111 106 19 20
QUETIAPINE FUMARATE 102 82 20 73
WARFARIN SODIUM 98 93 21 24
ZOLPIDEM TARTRATE 98 59 21 19
GABAPENTIN 98 78 21 12
PANTOPRAZOLE SODIUM 95 89 24 34
AMITRIPTYLINE HCL 87 60 R 25 43
METOPROLOL TARTRATE 79 50 26 15
PLAVIX 78 50 27 42
SERTRALINE HCL 77 55 28 26
CLONIDINE HCL 73 71 29 35
DIOVAN 72 68 30 33
METOPROLOL SUCCINATE 72 57 30 17
TRIAMTERENE-HCTZ 71 66 32 61
RISPERIDONE 68 67 33 78
DOXAZOSIN MESYLATE 68 56 33 70
NAPROXEN 65 58 35 84
PREDNISONE 65 58 35 47
OXYBUTYNIN CHLORIDE ER 64 43 37 154
ESCITALOPRAM OXALATE 64 48 37 51
TAMSULOSIN HCL 61 60 39 32
CLOPIDOGREL 58 53 40 28
NEXIUM 56 42 41 14
VERAPAMIL ER 55 54 42 87
SULFAMETHOXAZOLE-TRIMETHOPRIM 52 39 43 76
EXELON 52 52 43 113
FAMOTIDINE 51 41 45 90
ATORVASTATIN CALCIUM 51 42 45 13
MELOXICAM 50 50 47 18
ROPINIROLE HCL 50 41 47 93
PRAVASTATIN SODIUM 50 49 47 10
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 7, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.